Sp1198
EMERGING BLOOD BASED COLORECTAL CANCER SCREENING TESTS
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc). This session will provide expert guidance on the tests and their appropriate use in clinical care. LIVE STREAM SESSION
Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc). This session will provide expert guidance on the tests and their appropriate use in clinical care. LIVE STREAM SESSION
Presenter
Tracks
Related Products
PANEL DISCUSSION
Review updates and current considerations in colon cancer screening and surveillance related topics…
INTRODUCTION
SOCIETY: AGA
PANEL DISCUSSION
Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
